Ionis Pharmaceuticals Achieves Milestone with FDA Approval of Treatment for Familial Chylomicronemia Syndrome (FCS)
Ionis Pharmaceuticals marks a new commercial era with the FDA approval of Tryngolza, a novel RNA-targeted treatment for familial chylomicronemia syndrome, embarking on its first solo drug launch to address unmet medical needs.
Bipartisan Bill Introduces Key Healthcare Reforms to Enhance Transparency and Access
On December 18, 2024, U.S. lawmakers unveiled a bipartisan stopgap funding bill to finance the federal government through March, incorporating significant healthcare provisions.
Pfizer Projects $1 Billion Revenue Impact from IRA Changes and Foresees No Major M&A in 2025
Pfizer anticipates a $1 billion revenue reduction in 2025 due to Medicare Part D redesign while maintaining revenue forecasts. The company plans no major acquisitions, focusing instead on cost savings and operational growth.
Novo Nordisk Announces Significant Insulin Price Cuts for 2026
Novo Nordisk plans to reduce U.S. insulin prices significantly by 2026, aligning with Medicare mandates. The cuts follow industry trends and government pressure to lower diabetes treatment costs.
Biden Administration Proposes Expanding Medicare & Medicaid Coverage for Weight Loss Drugs
The Biden administration proposes a rule to allow Medicare and Medicaid to cover anti-obesity drugs like Wegovy and Zepbound, potentially providing access to millions but posing a $40 billion cost over a decade.
UPDATE: Eli Lilly Joins J&J in Challenging Federal 340B Drug Discount Program in Court
Eli Lilly and Johnson & Johnson have filed lawsuits against the U.S. government over the administration of the 340B drug discount program, seeking to implement rebate systems for hospitals instead of providing upfront drug discounts. The legal actions highlight ongoing tensions between pharmaceutical companies and healthcare providers over program costs and compliance.
Market Access “Back to School”: How to Plan and Prioritize Your 2025 Projects
Plan for 2025 in biopharma with insights on adapting to market changes, leveraging digital tools, and engaging key opinion leaders. Ensure guideline inclusion and stay competitive with strategic positioning. Use this checklist to prioritize initiatives for the evolving landscape.
Johnson & Johnson Challenges Federal Government Over 340B Rebate Plan
Johnson & Johnson has filed a lawsuit against the Biden administration, seeking to implement a rebate model for the 340B drug discount program. The pharmaceutical giant aims to replace upfront discounts with after-the-fact rebates, a move met with opposition from hospitals and federal regulators.
Senate Scrutiny on Pfizer and Lilly’s Telehealth Platforms Over Potential Anti-Kickback Violations
Pfizer and Eli Lilly face Senate inquiries over their telehealth prescription platforms amid concerns of potential violations of anti-kickback rules and inappropriate prescribing practices. Lawmakers are demanding clarity on these direct-to-patient programs.
ModEx: Revolutionizing Cancer Drug Pricing and Access Through Open-Source Health Economic Models
Discover how ModEx is transforming cancer drug pricing and accessibility by providing a decentralized platform for open-source health economic models. Learn about the innovative approach to model sharing, including royalty incentives for developers and enhanced validation for users, aimed at ensuring cost-effective healthcare solutions.
Battling the Superbug Crisis: Urgent Need for Innovative Solutions and Increased Funding
The escalating threat of antimicrobial resistance (AMR) is outpacing current efforts to develop effective treatments, leading [...]
Teva Settles $450 Million Kickback Allegations Over Copaxone Pricing Practices
Teva Pharmaceuticals USA and Teva Neuroscience have agreed to pay $450 million to settle allegations of [...]
Medicare Expansion for Weight Loss Drugs Estimated at $35 Billion
A Congressional Budget Office report estimates that expanding Medicare to cover weight loss drugs would cost [...]
Senate Hearing Debates Novo Nordisk Drug Pricing and PBM Influence
In a US Senate hearing, Senator Bernie Sanders criticized Novo Nordisk for high prices on Ozempic [...]
DarioHealth Secures New Employer Contract to Expand Cardiometabolic Solutions
Global leader in digital health DarioHealth announced a new contract with a national employer to provide [...]
FingerPost Consulting Ltd
At FingerPost Consulting, we support the leaders of BioTech and Pharmaceutical companies by providing market access and pricing strategy, insight, [...]
Rebuilding Public Trust in the Pharmaceutical Industry
The pharmaceutical industry faces trust issues despite recent successes and goodwill from its COVID-19 response. Public [...]
Medline Acquires Ecolab’s Surgical Solutions Division in $950 Million Deal
Medline is set to acquire Ecolab's surgical solutions division for nearly $1 billion, increasing their presence [...]
Podcast Q&A: Cell & Gene Therapies
In this episode of tHEORetically Speaking, join Dr. Pamela Landsman-Blumberg, Amanda O’Hora, and Ajay Keshava from Magnolia Market Access, who answer questions from a recent webinar on how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.
Eli Lilly Settles Lawsuit with Minnesota to Cap Insulin Prices at $35 and Donate to Clinics
Eli Lilly has agreed to a settlement to provide low-cost insulin to Minnesota patients, addressing a [...]
House Hearing Addresses Drug Shortages and Manufacturing Challenges in the U.S.
At a House Ways and Means Committee hearing, the issue of chronic drug shortages in the [...]
ICER Report: Price Hikes for Eight Drugs Lead to $1.3 Billion Increase in U.S. Healthcare Costs
The Institute for Clinical and Economic Review (ICER) reported that price increases for eight drugs led [...]
NIH’s New Director Monica Bertagnolli Concerned about Obesity; Emphasizes the Importance of Clinical Trials and Role of Insurers in Healthcare Research
Newly appointed NIH director Monica Bertagnolli expressed her concern about obesity and highlighted the importance of [...]
Real-World Data Empowers Pharma Advertising: An Interview with PurpleLab CEO Mark Brosso
In a conversation with Mark Brosso, the CEO of PurpleLab, it was uncovered that the pharmaceutical [...]
U.S. Men’s Life Expectancy Gap Widens to Largest Since 1996 Amid Public Health Crises and Covid-19 Impact
The life expectancy of men in the U.S. is about six years shorter than women, according [...]
